These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 15807628)

  • 1. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.
    Cai K; Gierman TM; Hotta J; Stenland CJ; Lee DC; Pifat DY; Petteway SR
    BioDrugs; 2005; 19(2):79-96. PubMed ID: 15807628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.
    Miller JL; Petteway SR; Lee DC
    J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S91-4. PubMed ID: 11586272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
    Lee DC; Miller JL; Petteway SR
    Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanofiltration of plasma-derived biopharmaceutical products.
    Burnouf T; Radosevich M
    Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
    Klamroth R; Gröner A; Simon TL
    Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance of prions during plasma protein manufacture.
    Burdick MD; Pifat DY; Petteway SR; Cai K
    Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies.
    Cai K; Gröner A; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gajardo R; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Lee DC; Moscardini M; Pölsler G; Roth NJ
    Transfusion; 2013 Sep; 53(9):1894-905. PubMed ID: 23252676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of coagulation factor concentrates.
    Teitel JM
    Haemophilia; 1998 Jul; 4(4):393-401. PubMed ID: 9873760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of adsorptive columns for specific pathogen removal: application to staphylococcal enterotoxin B.
    Wang G; Carbonell RG
    Biotechnol Prog; 2006; 22(5):1358-67. PubMed ID: 17022675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern plasma fractionation.
    Burnouf T
    Transfus Med Rev; 2007 Apr; 21(2):101-17. PubMed ID: 17397761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Process scale considerations in evaluation studies and scale-up.
    Walter JK; Werz W; Berthold W
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline -- a market survey.
    Berger CN; Le Donne P; Windemann H
    Biologicals; 2005 Mar; 33(1):1-7. PubMed ID: 15713551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
    Kempf C; Stucki M; Boschetti N
    Biologicals; 2007 Mar; 35(1):35-42. PubMed ID: 16581263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
    Rohwer RG
    Dev Biol Stand; 1996; 88():247-56. PubMed ID: 9119146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.